Overall, research activities are developed around three poles that range from the design of drugs (and the discovery of new targets) to their optimal use through all modern means of evaluation.
- Design and research of new active molecules pole include 3 research groups: Medicinal Chemistry (CMFA; rational basedsynthesis of new compounds) and Pharmacognosy (GNOS; extraction and identification of new active principles from plants). These two groups work in close collaboration with the research group focused on Bioanalysis and Pharmacology of Bioactive Lipids (BPBL), mainly for optimization of analytical procedures.
- Research focused on evaluation and characterisation of new targets are performed by Cellular and Molecular Pharmacology (FACM; pharmacology of antiinfective agents [mainly antibiotics]), Metabolism and Nutrition (MNUT; integrative physiology, metabolism and nutritional approaches) and Toxicology and Cancer Biology (GTOX; mechanisms leading to cell death).
- Finally, implementation and clinical evaluation research are covered by work performed by Pharmacokinetics and the Drug Metabolism (PKDM; effect of pathophysiological factors on pharmacokinetics), Pharmaceutics and Drug Delivery (FARG; developing new delivery systems for drugs, proteins, nucleic acids and antigens), Biomedical Magnetic Resonance (REMA; development of innovative tools using magnetic resonance with applications mainly in oncology) and Clinical Pharmacy (CLIP; evaluation of the quality of use in medicine and clinical practice).
All major aspects of the drug are covered from its design to its use.
The approaches use in vitro (membranes and cells) and in vivo models (small animals). Patients-oriented research is focused on population pharmacokinetics and clinical pharmacy.
A synopsis of the research themes is presented hereunder: